Literature DB >> 27622340

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Zoi Karoulia, Yang Wu, Tamer A Ahmed, Qisheng Xin, Julien Bollard, Clemens Krepler, Xuewei Wu, Chao Zhang, Gideon Bollag, Meenhard Herlyn, James A Fagin, Amaia Lujambio, Evripidis Gavathiotis, Poulikos I Poulikakos.   

Abstract

Entities:  

Year:  2016        PMID： 27622340     DOI： 10.1016/j.ccell.2016.08.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  14 in total

Review 1.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

2.  Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors.

Authors:  Chloe K Lombard; Audrey L Davis; Takayuki Inukai; Dustin J Maly
Journal:  Biochemistry       Date:  2018-09-25       Impact factor: 3.162

3.  The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.

Authors:  Mahamat Babagana; Julia V Kichina; Hannah Slabodkin; Sydney Johnson; Alexei Maslov; Lorin Brown; Kristopher Attwood; Mikhail A Nikiforov; Eugene S Kandel
Journal:  Mol Carcinog       Date:  2019-09-30       Impact factor: 4.784

4.  Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.

Authors:  Rikhia Chakraborty; Thomas M Burke; Oliver A Hampton; Daniel J Zinn; Karen Phaik Har Lim; Harshal Abhyankar; Brooks Scull; Vijetha Kumar; Nipun Kakkar; David A Wheeler; Angshumoy Roy; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; D Williams Parsons; Carl E Allen
Journal:  Blood       Date:  2016-10-11       Impact factor: 22.113

5.  Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.

Authors:  Amber Y Gunderwala; Anushri A Nimbvikar; Nicholas J Cope; Zhijun Li; Zhihong Wang
Journal:  ACS Chem Biol       Date:  2019-06-17       Impact factor: 5.100

6.  Mechanism of BRAF Activation through Biochemical Characterization of the Recombinant Full-Length Protein.

Authors:  Nicholas Cope; Christine Candelora; Kenneth Wong; Sujeet Kumar; Haihan Nan; Michael Grasso; Borna Novak; Yana Li; Ronen Marmorstein; Zhihong Wang
Journal:  Chembiochem       Date:  2018-08-17       Impact factor: 3.164

7.  RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.

Authors:  Ting Jin; Hugo Lavoie; Malha Sahmi; Maud David; Christine Hilt; Amy Hammell; Marc Therrien
Journal:  Nat Commun       Date:  2017-10-31       Impact factor: 14.919

Review 8.  Targeting the Raf kinases in human cancer: the Raf dimer dilemma.

Authors:  David E Durrant; Deborah K Morrison
Journal:  Br J Cancer       Date:  2017-12-14       Impact factor: 7.640

9.  Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.

Authors:  Florian Selt; Juliane Hohloch; Thomas Hielscher; Felix Sahm; David Capper; Andrey Korshunov; Diren Usta; Sebastian Brabetz; Johannes Ridinger; Jonas Ecker; Ina Oehme; Jan Gronych; Viktoria Marquardt; David Pauck; Heidi Bächli; Charles D Stiles; Andreas von Deimling; Marc Remke; Martin U Schuhmann; Stefan M Pfister; Tilman Brummer; David T W Jones; Olaf Witt; Till Milde
Journal:  Oncotarget       Date:  2017-02-14

10.  A systematic analysis of signaling reactivation and drug resistance.

Authors:  Boris N Kholodenko; Nora Rauch; Walter Kolch; Oleksii S Rukhlenko
Journal:  Cell Rep       Date:  2021-05-25       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.